The study, in Science Translational Medicine, assessed the antihistamine's impacts chlorcyclizine HCl (CCZ) on human liver cells united into mice. The analysts found that the medication weakened the infection's capacity to enter liver cells, keeping the early phase of HCV disease. This result was like that created by regular antiviral medications, however without a considerable lot of the antagonistic occasions frequently connected with such medications.
"Utilizing a creative highthroughput screening procedure, we distinguished CCZ as a strong inhibitor of hepatitis C," said analyst Anton Simeonov, PhD, the acting investigative executive of the National Institutes of Health National Center for Advancing Translational Sciences, in a press discharge. "Recognizing effectively sanction drugs from the NCATS Pharmaceutical Collection may offer a speedier course to potential disclosure of medicines for all ailments."
"In spite of the fact that hepatitis C is reparable, there is an unmet requirement for successful and moderate medicine," included lead creator T. Jake Liang, MD. "CCZ is a promising possibility for some piece of a treatment regimen for this conceivably lifethreatening malady."
The scientists plan to ponder the drug's consequences for individuals, however forewarned that CCZ ought not be utilized to treat HCV disease until it has been shown that the medication can be utilized securely and adequately for that reason.
An
OTC drug used to alleviate allergy symptoms could treat hepatitis C
virus (HCV) infection as well, according to the results of a recent
study.
The study, in Science Translational Medicine, evaluated the effects of the antihistamine chlorcyclizine HCl (CCZ) on human liver cells grafted into mice. The researchers found that the drug impaired the virus’ ability to enter liver cells, preventing the early stage of HCV infection. This outcome was similar to that produced by common antiviral drugs, but without many of the adverse events often associated with such drugs.
“Using an innovative highthroughput screening process, we identified CCZ as a potent inhibitor of hepatitis C,” said researcher Anton Simeonov, PhD, the acting scientific director of the National Institutes of Health National Center for Advancing Translational Sciences, in a press release. “Identifying already approved drugs from the NCATS Pharmaceutical Collection may offer a faster route to potential discovery of treatments for all diseases.”
“Although hepatitis C is curable, there is an unmet need for effective and affordable medication,” added lead author T. Jake Liang, MD. “CCZ is a promising candidate for part of a treatment regimen for this potentially lifethreatening disease.”
The researchers plan to study the drug’s effects on people, but cautioned that CCZ should not be used to treat HCV infection until it has been demonstrated that the drug can be used safely and effectively for that purpose. - See more at: http://www.pharmacytimes.com/publications/issue/2015/september2015/hepatitis-c-activity-inhibited-by-otc-allergy-drug#sthash.ZKCLjaRi.dpuf
The study, in Science Translational Medicine, evaluated the effects of the antihistamine chlorcyclizine HCl (CCZ) on human liver cells grafted into mice. The researchers found that the drug impaired the virus’ ability to enter liver cells, preventing the early stage of HCV infection. This outcome was similar to that produced by common antiviral drugs, but without many of the adverse events often associated with such drugs.
“Using an innovative highthroughput screening process, we identified CCZ as a potent inhibitor of hepatitis C,” said researcher Anton Simeonov, PhD, the acting scientific director of the National Institutes of Health National Center for Advancing Translational Sciences, in a press release. “Identifying already approved drugs from the NCATS Pharmaceutical Collection may offer a faster route to potential discovery of treatments for all diseases.”
“Although hepatitis C is curable, there is an unmet need for effective and affordable medication,” added lead author T. Jake Liang, MD. “CCZ is a promising candidate for part of a treatment regimen for this potentially lifethreatening disease.”
The researchers plan to study the drug’s effects on people, but cautioned that CCZ should not be used to treat HCV infection until it has been demonstrated that the drug can be used safely and effectively for that purpose. - See more at: http://www.pharmacytimes.com/publications/issue/2015/september2015/hepatitis-c-activity-inhibited-by-otc-allergy-drug#sthash.ZKCLjaRi.dpuf
An
OTC drug used to alleviate allergy symptoms could treat hepatitis C
virus (HCV) infection as well, according to the results of a recent
study.
The study, in Science Translational Medicine, evaluated the effects of the antihistamine chlorcyclizine HCl (CCZ) on human liver cells grafted into mice. The researchers found that the drug impaired the virus’ ability to enter liver cells, preventing the early stage of HCV infection. This outcome was similar to that produced by common antiviral drugs, but without many of the adverse events often associated with such drugs.
“Using an innovative highthroughput screening process, we identified CCZ as a potent inhibitor of hepatitis C,” said researcher Anton Simeonov, PhD, the acting scientific director of the National Institutes of Health National Center for Advancing Translational Sciences, in a press release. “Identifying already approved drugs from the NCATS Pharmaceutical Collection may offer a faster route to potential discovery of treatments for all diseases.”
“Although hepatitis C is curable, there is an unmet need for effective and affordable medication,” added lead author T. Jake Liang, MD. “CCZ is a promising candidate for part of a treatment regimen for this potentially lifethreatening disease.”
The researchers plan to study the drug’s effects on people, but cautioned that CCZ should not be used to treat HCV infection until it has been demonstrated that the drug can be used safely and effectively for that purpose. - See more at: http://www.pharmacytimes.com/publications/issue/2015/september2015/hepatitis-c-activity-inhibited-by-otc-allergy-drug#sthash.ZKCLjaRi.dpuf
The study, in Science Translational Medicine, evaluated the effects of the antihistamine chlorcyclizine HCl (CCZ) on human liver cells grafted into mice. The researchers found that the drug impaired the virus’ ability to enter liver cells, preventing the early stage of HCV infection. This outcome was similar to that produced by common antiviral drugs, but without many of the adverse events often associated with such drugs.
“Using an innovative highthroughput screening process, we identified CCZ as a potent inhibitor of hepatitis C,” said researcher Anton Simeonov, PhD, the acting scientific director of the National Institutes of Health National Center for Advancing Translational Sciences, in a press release. “Identifying already approved drugs from the NCATS Pharmaceutical Collection may offer a faster route to potential discovery of treatments for all diseases.”
“Although hepatitis C is curable, there is an unmet need for effective and affordable medication,” added lead author T. Jake Liang, MD. “CCZ is a promising candidate for part of a treatment regimen for this potentially lifethreatening disease.”
The researchers plan to study the drug’s effects on people, but cautioned that CCZ should not be used to treat HCV infection until it has been demonstrated that the drug can be used safely and effectively for that purpose. - See more at: http://www.pharmacytimes.com/publications/issue/2015/september2015/hepatitis-c-activity-inhibited-by-otc-allergy-drug#sthash.ZKCLjaRi.dpuf
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.